Top-Rated StocksTop-RatedNASDAQ:ACLX Arcellx (ACLX) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free ACLX Stock Alerts $52.00 +0.35 (+0.68%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$50.54▼$53.3550-Day Range$51.65▼$73.4952-Week Range$30.74▼$75.10Volume438,386 shsAverage Volume437,044 shsMarket Capitalization$2.77 billionP/E RatioN/ADividend YieldN/APrice Target$74.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Arcellx alerts: Email Address Arcellx MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside42.6% Upside$74.17 Price TargetShort InterestBearish9.85% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 6 Articles This WeekInsider TradingSelling Shares$42.44 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.69) to ($1.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.77 out of 5 starsMedical Sector400th out of 910 stocksBiological Products, Except Diagnostic Industry59th out of 153 stocks 4.5 Analyst's Opinion Consensus RatingArcellx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArcellx has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.85% of the float of Arcellx has been sold short.Short Interest Ratio / Days to CoverArcellx has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Arcellx has recently increased by 4.43%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldArcellx does not currently pay a dividend.Dividend GrowthArcellx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACLX. Previous Next 1.9 News and Social Media Coverage News SentimentArcellx has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Arcellx this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for ACLX on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Arcellx to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcellx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,439,893.00 in company stock.Percentage Held by InsidersOnly 6.24% of the stock of Arcellx is held by insiders.Percentage Held by Institutions96.03% of the stock of Arcellx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcellx are expected to grow in the coming year, from ($1.69) to ($1.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcellx is -35.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcellx is -35.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcellx has a P/B Ratio of 5.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Arcellx Stock (NASDAQ:ACLX)Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Read More ACLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACLX Stock News HeadlinesApril 19, 2024 | insidertrades.comArcellx, Inc. (NASDAQ:ACLX) Director Olivia C. Ware Sells 9,402 SharesApril 4, 2024 | insidertrades.comArcellx, Inc. (NASDAQ:ACLX) Insider Rami Elghandour Sells 23,086 SharesApril 23, 2024 | The Bull Report (Ad)Healthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.March 27, 2024 | insidertrades.comArcellx, Inc. (NASDAQ:ACLX) Insider Christopher Heery Sells 5,450 SharesMarch 27, 2024 | insidertrades.comArcellx, Inc. (NASDAQ:ACLX) Insider Sells $2,902,995.70 in StockMarch 26, 2024 | insidertrades.comArcellx, Inc. (NASDAQ:ACLX) Director Sells $35,575,754.65 in StockApril 20, 2024 | americanbankingnews.comOlivia C. Ware Sells 9,402 Shares of Arcellx, Inc. (NASDAQ:ACLX) StockApril 20, 2024 | americanbankingnews.comArcellx (NASDAQ:ACLX) Stock Price Down 3% on Insider SellingApril 23, 2024 | The Bull Report (Ad)Healthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.April 13, 2024 | americanbankingnews.comArcellx (NASDAQ:ACLX) Stock Rating Reaffirmed by Needham & Company LLCApril 12, 2024 | markets.businessinsider.comBuy Rating Backed by Potential Regulatory Tailwinds for Arcellx’s CAR-T TherapyApril 11, 2024 | msn.com3 Best Stocks to Buy Now, 4/11/2024, According to Top AnalystsApril 4, 2024 | businesswire.comArcellx to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceApril 4, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX) and Adaptive Biotechnologies (ADPT)March 27, 2024 | finance.yahoo.comInsider Sell: Arcellx Inc's Chief Medical Officer Christopher Heery Disposes of 46,815 SharesMarch 20, 2024 | investing.comArcellx director Ware sells over $630k in company stockMarch 20, 2024 | businesswire.comArcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceMarch 18, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Arcellx Inc (ACLX) and AdaptHealth (AHCO)March 16, 2024 | finance.yahoo.comACLX Apr 2024 70.000 callMarch 7, 2024 | realmoney.thestreet.comArcellx initiated with bullish view at Morgan Stanley, here's whyMarch 2, 2024 | finance.yahoo.comEarnings Update: Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Are Boosting Their EstimatesFebruary 29, 2024 | markets.businessinsider.comAnticipating Arcellx Inc. Catalysts: Strong CAR-T Trial Data Underpin Buy RatingFebruary 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arcellx Inc’s Anito-cel Amid Superior Safety Profile and Strong Market Entry ProspectsFebruary 29, 2024 | prnewswire.comArcellx to Participate at the TD Cowen 44th Annual Health Care ConferenceFebruary 29, 2024 | finanznachrichten.deArcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business HighlightsFebruary 29, 2024 | msn.comArcellx Analysts Boost Their Forecasts After Q4 ResultsFebruary 29, 2024 | markets.businessinsider.comWilliam Blair Reaffirms Their Buy Rating on Arcellx Inc (ACLX)See More Headlines Receive ACLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/23/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ACLX CUSIPN/A CIK1786205 Webarcellx.com Phone240-327-0603FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Stock Price Target$74.17 High Stock Price Target$87.00 Low Stock Price Target$50.00 Potential Upside/Downside+42.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,690,000.00 Net Margins-64.08% Pretax Margin-63.48% Return on Equity-20.96% Return on Assets-10.53% Debt Debt-to-Equity RatioN/A Current Ratio6.06 Quick Ratio6.06 Sales & Book Value Annual Sales$110.32 million Price / Sales25.12 Cash FlowN/A Price / Cash FlowN/A Book Value$9.97 per share Price / Book5.22Miscellaneous Outstanding Shares53,290,000Free Float49,965,000Market Cap$2.77 billion OptionableOptionable Beta0.02 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Rami Elghandour (Age 45)Chairman of the Board, CEO & President Comp: $1.02MMs. Michelle Lim Gilson (Age 31)Chief Financial Officer Comp: $832.8kDr. Christopher R. Heery M.D. (Age 44)Chief Medical Officer Comp: $688.55kMr. Narinderjeet Singh M.S. (Age 52)Chief Technical Officer Mr. David Tice Ph.D. (Age 53)Chief Scientific Officer Ms. Myesha LacyChief Investor & Communications OfficerMs. Maryam Abdul-Kareem J.D.M.S., General CounselMs. Kate AikenChief People OfficerMr. Neeraj P. Teotia (Age 49)Chief Commercial Officer Comp: $461.95kMs. Aileen FernandesChief Business OfficerMore ExecutivesKey CompetitorsApogee TherapeuticsNASDAQ:APGESpringWorks TherapeuticsNASDAQ:SWTXImmunocoreNASDAQ:IMCRIovance BiotherapeuticsNASDAQ:IOVAImmunityBioNASDAQ:IBRXView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 11,556 shares on 4/18/2024Ownership: 0.022%Olivia C. WareSold 9,402 sharesTotal: $522,281.10 ($55.55/share)High Net Worth Advisory Group LLCBought 1,000 shares on 4/12/2024Ownership: 0.015%Congress Asset Management Co. MASold 1,831 shares on 4/11/2024Ownership: 0.044%Rami ElghandourSold 23,086 sharesTotal: $1.55 M ($67.09/share)View All Insider TransactionsView All Institutional Transactions ACLX Stock Analysis - Frequently Asked Questions Should I buy or sell Arcellx stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACLX shares. View ACLX analyst ratings or view top-rated stocks. What is Arcellx's stock price target for 2024? 12 Wall Street analysts have issued 12-month price objectives for Arcellx's stock. Their ACLX share price targets range from $50.00 to $87.00. On average, they predict the company's share price to reach $74.17 in the next year. This suggests a possible upside of 42.6% from the stock's current price. View analysts price targets for ACLX or view top-rated stocks among Wall Street analysts. How have ACLX shares performed in 2024? Arcellx's stock was trading at $55.50 at the start of the year. Since then, ACLX shares have decreased by 6.3% and is now trading at $52.00. View the best growth stocks for 2024 here. When is Arcellx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our ACLX earnings forecast. How were Arcellx's earnings last quarter? Arcellx, Inc. (NASDAQ:ACLX) announced its quarterly earnings data on Wednesday, February, 28th. The company reported $0.42 earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.95. The business had revenue of $63.15 million for the quarter, compared to analyst estimates of $20.07 million. Arcellx had a negative net margin of 64.08% and a negative trailing twelve-month return on equity of 20.96%. During the same period last year, the company earned ($0.76) earnings per share. What ETFs hold Arcellx's stock? ETFs with the largest weight of Arcellx (NASDAQ:ACLX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), ALPS Medical Breakthroughs ETF (SBIO), Tema Oncology ETF (CANC), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Harbor Human Capital Factor US Small Cap ETF (HAPS) and Principal Healthcare Innovators ETF (BTEC).First Trust Nasdaq Pharmaceuticals ETF (FTXH). When did Arcellx IPO? Arcellx (ACLX) raised $132 million in an IPO on Friday, February 4th 2022. The company issued 8,250,000 shares at $15.00-$17.00 per share. Who are Arcellx's major shareholders? Arcellx's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Congress Asset Management Co. MA (0.04%), Allspring Global Investments Holdings LLC (0.02%) and High Net Worth Advisory Group LLC (0.02%). Insiders that own company stock include Christopher Heery, Enterprise Associates 15 New, Jill Carroll, Michelle Gilson, Olivia C Ware, Rami Elghandour, Scott D Sandell and Sr One Capital Management, Llc. View institutional ownership trends. How do I buy shares of Arcellx? Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACLX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcellx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
